Investor Relations

Overview

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

read more

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

AnaptysBio Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option

SAN DIEGO , Sept. 28, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the closing of its underwritten public offering of 2,530,000

AnaptysBio Announces Pricing of Public Offering of Common Stock

SAN DIEGO , Sept. 25, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the pricing of its underwritten public offering of 2,200,000

AnaptysBio Announces Proposed Public Offering of Common Stock

SAN DIEGO , Sept. 24, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that it intends to offer $200.0 million of its common stock in